Company profile

AbCellera

Pipeline4 assets

ABCL635ABCL635 / NK3R / antibody medicine / Endocrinology / Women's Health
Vasomotor Symptoms (VMS) associated with menopausePhase 2active
ABCL575ABCL575 / OX40L / monoclonal antibody / Immunology & Inflammation
Atopic Dermatitis (AD)Phase 1active
ABCL688ABCL688 / Undisclosed GPCR / Ion Channel / antibody medicine / Autoimmunity
Undisclosed autoimmunity indicationIND-Enablingactive
ABCL386ABCL386 / Undisclosed / antibody medicine / Oncology
Undisclosed oncology indicationIND-Enablingactive

Latest news10 items

May 11, 2026

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 7, 2026

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

Apr 20, 2026

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

Apr 1, 2026

AbCellera to Report First Quarter 2026 Financial Results on May 11, 2026

Feb 24, 2026

AbCellera Reports Full Year 2025 Business Results

Feb 11, 2026

AbCellera to Present at Upcoming Investor Conferences in March and April 2026

Jan 22, 2026

AbCellera to Report Full Year 2025 Financial Results on February 24, 2026

Jan 12, 2026

AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause

Trial Start • Phase 2

Dec 18, 2025

AbCellera and Bruker Reach Global Settlement of Patent Litigation

Dec 8, 2025

AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026

AbCellera • Endpoint Arena